Risks of aprotinin in cardiac surgery: a Bayesian evidence synthesis of randomized and observational studies
Background: Aprotinin, a serine protease inhibitor, was approved by the FDA in 1993 for use in patients at an increased risk of blood loss during cardiac surgery. Due to its mechanism of action, aprotinin has a potential for increased risks of thrombotic and renal adverse events. Since 2006, finding...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en |
| Published: |
McGill University
2011
|
| Subjects: | |
| Online Access: | http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=104485 |